Sean Laaman, an analyst from Morgan Stanley, has initiated a new Buy rating on Argenx Se (ARGX).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sean Laaman has given his Buy rating due to a combination of factors including Argenx’s strong growth prospects and strategic positioning in the market. The company is expected to achieve a significant increase in product revenue, driven by the expansion of Vyvgart’s indications and market reach. This growth is supported by positive feedback from key opinion leaders and an anticipated uptake in the treatment of CIDP patients.
Moreover, Argenx is on track to become profitable by 2025, which enhances its financial outlook. The potential for Vyvgart to expand into additional indications presents further opportunities for revenue growth, with projections indicating substantial sales increases by 2030. These factors, combined with a promising pipeline and strategic developments, underpin Laaman’s positive outlook and the Overweight rating for Argenx’s stock.
According to TipRanks, Laaman is a 3-star analyst with an average return of 2.9% and a 55.03% success rate. Laaman covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Halozyme, and Jazz Pharmaceuticals.
In another report released on July 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $720.00 price target.